Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary

The rapid development of angiogenic growth factor therapy for patients with advanced ischemic heart disease over the last 5 years offers hope of a new treatment strategy based on generation of new blood supply in the diseased heart. However, as the field of therapeutic coronary angiogenesis is matur...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2000-09, Vol.102 (11), p.E73-E86
Main Authors: Simons, M, Bonow, R O, Chronos, N A, Cohen, D J, Giordano, F J, Hammond, H K, Laham, R J, Li, W, Pike, M, Sellke, F W, Stegmann, T J, Udelson, J E, Rosengart, T K
Format: Article
Language:English
Subjects:
Angiogenesis Inducing Agents - adverse effects
Angiogenesis Inducing Agents - genetics
Angiogenesis Inducing Agents - therapeutic use
Animals
Clinical Trials as Topic
Coronary Angiography
Coronary Vessels
Endothelial Growth Factors - adverse effects
Endothelial Growth Factors - genetics
Endothelial Growth Factors - therapeutic use
Fibroblast Growth Factor 2 - adverse effects
Fibroblast Growth Factor 2 - genetics
Fibroblast Growth Factor 2 - therapeutic use
Genetic Therapy - adverse effects
Heart Diseases - diagnostic imaging
Heart Diseases - therapy
Humans
Lymphokines - adverse effects
Lymphokines - genetics
Lymphokines - therapeutic use
Magnetic Resonance Imaging
Neovascularization, Physiologic
Patient Selection
Tomography, Emission-Computed
Tomography, Emission-Computed, Single-Photon
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rapid development of angiogenic growth factor therapy for patients with advanced ischemic heart disease over the last 5 years offers hope of a new treatment strategy based on generation of new blood supply in the diseased heart. However, as the field of therapeutic coronary angiogenesis is maturing from basic and preclinical investigations to clinical trials, many new and presently unresolved issues are coming into focus. These include in-depth understanding of the biology of angiogenesis, selection of appropriate patient populations for clinical trials, choice of therapeutic end points and means of their assessment, choice of therapeutic strategy (gene versus protein delivery), route of administration, and the side effect profile. The present article presents a summary statement of a panel of experts actively working in the field, convened by the Angiogenesis Foundation and the Angiogenesis Research Center during the 72nd meeting of the American Heart Association to define and achieve a consensus on the challenges facing development of therapeutic angiogenesis for coronary disease.
ISSN:0009-7322
1524-4539
DOI:10.1161/01.CIR.102.11.e73